Tracking spinal fluid flow in the brain with MRI contrast dye
Tests Gadovist given in the spinal canal, tracked by MRI, in adults.
Key facts
- Who runs it
- Region Vaesterbotten
- Where
- Umea, SwedenSee the site
- Registry title
- MRI contrast agent in the spinal canal to investigate transportation of the cerebrospinal fluid in the brain.
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 135 people, planned
- Started
- 13 Jan 2025
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional
- Record updated
- 23 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people being checked for suspected idiopathic normal pressure hydrocephalus at Umeå University hospital, people with Alzheimer's disease, and healthy volunteers. They get a contrast agent (Gadovist) into the spinal canal, then repeated MRI scans to see how the fluid around the brain moves.
- Age
- 18 Years and older. People with suspected normal pressure hydrocephalus must be 65 or older. People with Alzheimer's disease and healthy volunteers must be 55 years or older.
- Sex
- All sexes can join.
- Disease stage
- Suspected idiopathic normal pressure hydrocephalus (fluid build-up in the brain with no known cause), or Alzheimer's disease. Healthy volunteers can also join.
- Earlier treatment
- People who have had a test with a gadolinium contrast agent before cannot join. People now taking blood thinners cannot join.
- Biomarker or test result
- A memory test score (MMSE) of 20 or higher is needed.
Main reasons for not taking part
- Liver failure or reduced kidney function (shown by a blood test at admission)
- Cannot understand the instructions needed to give consent
- Known allergies that rule out the contrast agent, or reasons you cannot have an MRI
- Seizures happen easily, or a history of bronchial asthma
- Current treatment with blood thinners, or an earlier test with gadolinium contrast
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patients investigated for suspected idiopathic normal pressure hydrocephalus at Umeå University hospital
- Patients with Alzheimers disease
- Healthy controls
Who cannot take part
- Current treatment with anticoagulation medication
- Previous investigation with gadolinium contrast medium
- Liver failure
- known contradicting allergies
- Renal impairment (as deffined by blood test at admission)
- Low threshold for seizures
- History of bronchial asthma
- Age <65 for INPH. Age <55 years for AD and HC
- Mini mental state examination (MMSE) < 20
- Not able to understand instructions needed for informed concent
- Known contraindications for magnetic reconance imaging
Where in Sweden
- Region VaesterbottenUmea, SwedenTaking people
About the trial
What the trial wants to find out
To quantify the distribution and rate of elimination of the contrast agent as assessed by repeated MRI in humans. We will also document any adverse events related to the administration of Gadovist
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Intrathecal contrast-enhanced MRI for investigation of cerebrospinal fluid transportation
- Plain-language title
- Tracking spinal fluid flow in the brain with MRI contrast dyeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 23 July 2026